Fungemia in cancer patients undergoing chemotherapy versus surgery: Risk factors, etiology and outcome

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 3, 1997, Pages 301-304

  Kralovicova, K ^a   Spanik, S ^c   Oravcova, E ^a   Mrazova, M ^a   Morova, E ^a   Gulikova, V ^a   Kukuckova, E ^a   Koren, P ^a   Pichna, P ^a   Nogova, J ^a   Kunova, A ^b   Trupl, J ^b   Krcmery Jr , V ^a,d  

^a TRNAVA UNIVERSITY   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c ST ELIZABETH CANCER INSTITUTE   (Slovakia)

^d School of Health Sciences   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; FLUCONAZOLE; KETOCONAZOLE; MICONAZOLE; NETILMICIN; OFLOXACIN; PENICILLIN G; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANDIDA ALBICANS; CATHETER; CHEMOPROPHYLAXIS; FUNGEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RISK FACTOR; TREATMENT OUTCOME;

EID: 0347833014     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709019047     Document Type: Article

References (11)

1. Rex J and the Candidemia study group. A randomized trial comparing fluconazole vs Amphotericin B for the treatment of Candidemia. N Engl J Med 331: 1325-1330, 1994.
2. EORTC Antimicrobial study group. Empiric fungal therapy in granulocytopenic cancer patients. Am J Med 86: 886-892, 1989.
3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 148: 2642-2655, 1988.
4. Fraser VJ, Dunagan WC. Candidemia in a tertiary care hospital. Epidemiology, risk factors and predictors of mortality. Clin Infect Dis 15: 414-421, 1992.
5. Rex JH, Bennet JE, Sugar AM. Randomised trial comparing Fluconazol with Amphotericin B for treatment of candidaemia in patient without neutropenia. N Engl J Med 331: 1325-1330, 1994.
6. Wingard JR. Importance of Candida spp. other than C. albicans as pathogens in oncology patients. Clin Infect Dis 10: 115-125, 1995.
7. Viscoli C, and the EORTC IFICG study group: European study of Candidemia in cancer patients [Abstract No. 134] 7th ECCMID, Vienna, 16 30 March, 1995.
8. Bulmberg EA, Reboli AC. Failure of systemic empirical treatment with Amphotericin B to prevent candidaemia in neutropenic patients with cancer. Clin Infect Dis 22: 462-466, 1996.
9. Hughes W, and the IDSA panel. Guidelines for empiric therapy of neutropenic patients with unexplained fever. J Infect Dis 53: 1133, 1990.
10. Martino P. Fusarium infections in cancer patients: J Infect 32: 26, 1994.
11. Giamarellou H, Antomiadou A. Epidemiology diagnosis and therapy of fungal infections in surgery. Infect Control Hosp Epidemiol 17: 558-564, 1996.